Status:
RECRUITING
Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF)
Lead Sponsor:
Barts & The London NHS Trust
Conditions:
Persistent Atrial Fibrillation
Cardiac Arrhythmia
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
The main aim of the research is to investigate whether patients undergoing pulmonary vein isolation with catheter ablation for persistent atrial fibrillation (AF) will have lower rates of AF recurrenc...
Detailed Description
After adequate stroke prevention (e.g. anticoagulation) and rate control, the optimum strategy for patients who continue to be symptomatic with persistent AF has not been established. Cardioversion wi...
Eligibility Criteria
Inclusion
- Ability to give informed consent
- Age 18-85 years
- Persistent AF (atrial fibrillation lasting \> 7days) of total continuous duration \<2 years as documented in medical notes.
- Patients being considered for cardioversion.
Exclusion
- Creatinine clearance (eGFR) \< 30mls/min
- Contraindication or unable to take anticoagulation
- Uncontrolled hypertension
- Contraindication for catheter ablation
- BMI \> 40
- Patients in Persistent AF who have had more than one previous cardioversion.
- Established diagnosis of Hypertrophic cardiomyopathy
Key Trial Info
Start Date :
July 26 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 5 2027
Estimated Enrollment :
208 Patients enrolled
Trial Details
Trial ID
NCT06096246
Start Date
July 26 2024
End Date
December 5 2027
Last Update
September 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barts Heart Centre
London, United Kingdom, EC1A 7BE